Sunday, 24 September 2023

News Feed
Most Popular
Pharma News
BioTech News
MedTech News
BioServices News
Video Gallery

Inside Magazine

Multipronged Approach Against Alzheimer’s Disease

In July 2023, Eisai and Biogen received full traditional approval from the United States Food and Drug Administration (US FDA) for their Alzheimer’s drug Leqembi (lecanemab-irmb). This drug is the first to target the disease’s progression rather than merely addressing its symptoms. The approval has infused excitement and hope into the field of Alzheimer’s drug development, known for frequent drug failures. Alzheimer’s Disease (AD) is an escalating global health crisis. In 2020, the World Health Organisation (WHO) noted over 50 million people had dementia worldwide; 60 per cent of them lived in low- to middle-income countries. The Asia Pacific region bears a hefty burden with dementia care costs at $185 billion, straining healthcare in populous economies, according to ADI (Alzheimer’s Disease International). As we mark World Alzheimer’s Day this year on September 21, let’s take a stock of the advancements in the research and development in the Asia Pacific.

For Feedback Email Us:

Click here to access E-magazine

BioSpectrum Infomercial

Automation & High Throughput with SUEZ's Sievers Eclipse BET Platform